Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2015

01-12-2015 | Commentary

The financial hazard of personalized medicine and supportive care

Authors: Pricivel M. Carrera, Ian Olver

Published in: Supportive Care in Cancer | Issue 12/2015

Login to get access

Abstract

Personalized medicine is revolutionizing the delivery of oncological care, promising benefits both at the patient and health system levels. The cost of targeted therapies, unfortunately, is becoming more expensive and unaffordable. Where supportive care in cancer concerns the prevention and management of the adverse effects of cancer and its treatment and is the thrust of the Multinational Association of Supportive Care in Cancer, financing of and value in personalized medicine is an important area of research and engagement for the association. Discussing patients’ concerns with and identifying those at most risk for the financial hazard of cancer treatment and offering financial counseling and assistance and/or referral to support networks are potential key areas for (exploring and providing) better supportive care. The time is now to turn the concern of patients and their carers, providers, and other advocates regarding the affordability of cancer treatment into a collective cause towards coordinated action.
Literature
1.
Stahel R, Peters S, Baas P et al (2013) Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 82:375–382CrossRefPubMed
2.
Carrera P, Ormond M (2015) Current practice in and considerations for personalized medicine in lung cancer: from the patient’s molecular biology to patient values and preferences. Maturitas 82:94–99
3.
Zafar SY, Abernethy AP (2013) Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park) 27:80–81, 149
4.
Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D (2014) High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract 10:e208–e211CrossRefPubMed
5.
Tucker-Seeley RD, Abel GA, Uno H, Prigerson H (2014) Financial hardship and the intensity of medical care received near death. Psychooncology 24:572–578CrossRefPubMed
6.
Shen YC, McFeeters J (2006) Out-of-pocket health spending between low-and higher-income populations: who is at risk of having high expenses and high burdens? Med Care 44:200–209CrossRefPubMed
7.
Himmelstein DU, Thorne D, Warren E, Woolhandler S (2009) Medical bankruptcy in the United States, 2007: results of a national study. Am J Med 122:741–746CrossRefPubMed
8.
Linley WG, Hughes DA (2013) Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 22:948–964CrossRefPubMed
9.
Kentikelenis A, Karanikolos M, Reeves A, McKee M, Stuckler D (2014) Greece’s health crisis: from austerity to denialism. Lancet 383(9918):748–753CrossRefPubMed
10.
Saloustros E, Vichas G, Margiolaki A, Koumiotaki S, Androulakis N, Georgoulias V (2014) Lung cancer in the era of Greek economic crisis. Lung Cancer 86(1):112–113CrossRefPubMed
11.
Rittenberg CN, Johnson JL, Kuncio GM (2010) An oral history of MASCC, its origin and development from MASCC’s beginnings to 2009. Support Care Cancer 18:775–784CrossRefPubMed
12.
Meropol NJ, Schrag D, Smith TJ et al (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868–3874CrossRefPubMed
13.
Olver I (2013) Challenges of accessing cancer medicines in Australia. Lancet Oncol 11:1040–1042CrossRef
14.
Smith SK, Nicolla J, Zafar SY (2014) Bridging the gap between financial distress and available resources for patients with cancer: a qualitative study. J Oncol Pract 10:e368–e372CrossRefPubMed
15.
Chan A, Chiang YY, Low XH, Yap KY, Ng R (2013) Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. Support Care Cancer 21:3509–3517CrossRefPubMed
16.
Prawitz AD, Garman ET, Sorhaindo B et al (2006) InCharge Financial Distress/Financial Well-Being Scale: development, administration, and score interpretation. J Financ Couns Plan 17:34–50
17.
de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120:3245–3253CrossRefPubMed
18.
Teng I, Spigelman A (2014) Attitudes and knowledge of medical practitioners to hereditary cancer clinics and cancer genetic testing. Fam Cancer 13(2):311–324CrossRefPubMed
19.
Henrikson NB, Tuzzio L, Loggers ET, Miyoshi J, Buist DS (2014) Patient and oncologist discussions about cancer care costs. Support Care Cancer 22:961–967PubMedCentralCrossRefPubMed
20.
Metadata
Title
The financial hazard of personalized medicine and supportive care
Authors
Pricivel M. Carrera
Ian Olver
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2922-3

Other articles of this Issue 12/2015

Supportive Care in Cancer 12/2015 Go to the issue

Original Article

Association of obesity and sleep problems among breast cancer survivors: results from a registry-based survey study

Letter to the editor

Response to editorial by Richard Crevenna, MD, regarding “cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services” by Silver et al.

Original Article

Difficult choices for young patients with cancer: the supportive role of decisional counseling

Original Article

How to implement quality indicators successfully in palliative care services: perceptions of team members about facilitators of and barriers to implementation

Original Article

Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy

Original Article

Cognitive strategies and quality of life of patients with high-grade glioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits